


# Mechanism of UCH-L5 Activation and Inhibition by DEUBAD Domains in RPN13 and INO80G

## Graphical Abstract



## Authors

Danny D. Sahtoe, Willem J. van Dijk, ..., Huib Ovaa, Titia K. Sixma

## Correspondence

t.sixma@nki.nl

## In Brief

Deubiquitinating enzyme UCH-L5 (UCH37) is involved in DNA repair and the proteasome system. Sahtoe et al. uncover how two evolutionarily related DEUBAD domains in RPN13 (ADRM1) and INO80G (NFRKB) can either activate or inhibit UCH-L5. These remarkable regulatory modes exploit flexible structural elements in UCH-L5 to modulate activity.

## Highlights

- The RPN13 DEUBAD domain activates UCH-L5 by positioning its CL and ULD domain
- The INO80G DEUBAD domain inhibits UCH-L5 by blocking ubiquitin binding
- The FRF hairpin in the DEUBAD domain of INO80G drives UCH-L5 inhibition
- DEUBAD domains regulate UCH-L5 activity by tuning UCH-L5 substrate affinity

## Accession Numbers

4UEM  
4UEL  
4UF5  
4UF6



# Mechanism of UCH-L5 Activation and Inhibition by DEUBAD Domains in RPN13 and INO80G

Danny D. Sahtoe,<sup>1</sup> Willem J. van Dijk,<sup>1</sup> Farid El Oualid,<sup>2,3</sup> Reggy Ekkebus,<sup>2</sup> Huib Ovaa,<sup>2</sup> and Titia K. Sixma<sup>1,\*</sup>

<sup>1</sup>Division of Biochemistry and Cancer Genomics Center

<sup>2</sup>Division of Cell Biology

The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands

<sup>3</sup>UbiQ, Science Park 408, 1098XH Amsterdam, the Netherlands

\*Correspondence: [t.sixma@nki.nl](mailto:t.sixma@nki.nl)

<http://dx.doi.org/10.1016/j.molcel.2014.12.039>

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## SUMMARY

Deubiquitinating enzymes (DUBs) control vital processes in eukaryotes by hydrolyzing ubiquitin adducts. Their activities are tightly regulated, but the mechanisms remain elusive. In particular, the DUB UCH-L5 can be either activated or inhibited by conserved regulatory proteins RPN13 and INO80G, respectively. Here we show how the DEUBAD domain in RPN13 activates UCH-L5 by positioning its C-terminal ULD domain and crossover loop to promote substrate binding and catalysis. The related DEUBAD domain in INO80G inhibits UCH-L5 by exploiting similar structural elements in UCH-L5 to promote a radically different conformation, and employs molecular mimicry to block ubiquitin docking. In this process, large conformational changes create small but highly specific interfaces that mediate activity modulation of UCH-L5 by altering the affinity for substrates. Our results establish how related domains can exploit enzyme conformational plasticity to allosterically regulate DUB activity. These allosteric sites may present novel insights for pharmaceutical intervention in DUB activity.

## INTRODUCTION

The ubiquitin conjugation machinery regulates almost every process in the eukaryotic cell. Deubiquitinating enzymes (DUBs) are a critical component of the machinery since they can remove ubiquitin adducts and thereby control the level of ubiquitin signals (Komander et al., 2009). In accordance with their important roles, DUBs are frequently deregulated in human pathologies including cancer and neurological disease (Clague et al., 2013), making DUBs potential prime targets for therapeutic intervention.

The level of the intrinsic DUB activity is important and requires precise control. For a subset of DUBs, there is emerging evidence that the catalytic activity can be modulated by regulatory proteins or by internal domains (Sowa et al., 2009). Notable ex-


amples include USP7 activation by its HUBL domain and GMPs (Faesen et al., 2011), USP1 activation by UAF1 (Cohn et al., 2007), and Ubp8 activation in the SAGA complex (Köhler et al., 2008; Lee et al., 2005). The most striking example is UCH-L5, for which both activation and inhibition have been observed (Hamazaki et al., 2006; Qiu et al., 2006; Yao et al., 2006, 2008) by two different proteins, RPN13 (ADRM1) and INO80G (NFRKB), respectively.

Understanding the mechanisms of DUB activation is important for interpreting their roles in specific cellular contexts. Mechanistic insight into regulatory mechanisms also can provide vital information for the development of inhibitors or activators. So far, the only available crystal structure of a DUB-activator complex is that of the SAGA DUB module (Köhler et al., 2010; Samara et al., 2010), but no structure is available for its inactive state. Due to this lack of structural data, detailed mechanisms of DUB regulation are still poorly understood.

UCH-L5 (UCH37) is a cysteine protease of the ubiquitin C-terminal hydrolase (UCH) family of DUBs, which also includes UCH-L1, UCH-L3, and BAP1. UCH-L5 is overexpressed in several carcinomas (Chen et al., 2012; Fang et al., 2012, 2013) and knockout of the gene is embryonically lethal in mice (Al-Shami et al., 2010). Functionally, it has been linked to TGF- $\beta$  signaling, Alzheimer's disease, and longevity (Kikuchi et al., 2013; Matilainen et al., 2013; Wicks et al., 2005, 2006). UCH-L5 constitutes a component of proteasomes and INO80 chromatin remodeling complexes, where it is activated and inhibited, respectively.

As a non-essential component of the proteasome 19S regulatory particle, UCH-L5 catalyzes K48-linked polyubiquitin hydrolysis. This activity requires the RPN13 subunit whose C-terminal domain binds UCH-L5 (Hamazaki et al., 2006; Qiu et al., 2006; Yao et al., 2006). In vitro, RPN13 is able to directly promote UCH-L5 activity against a minimal substrate (Hamazaki et al., 2006; Qiu et al., 2006; Yao et al., 2006).

UCH-L5 has a less well-defined role in metazoan INO80 chromatin remodeling complexes. INO80 is an essential determinant of embryonic stem cell identity (Chia et al., 2010; Wang et al., 2014) and participates in the DNA damage response (Smeenk and van Attikum, 2013), but the function of the metazoan-specific subunits, such as INO80G, is poorly defined. A recent report has implicated UCH-L5 and INO80G as key factors of the DNA double-strand-break response (Nishi et al., 2014). Interestingly, in the context of the INO80 complex, the DUB activity of



(legend on next page)

UCH-L5 is inhibited by the INO80G subunit (Yao et al., 2008). Intriguingly, an artificial shorter version of INO80G was found to activate UCH-L5 in vitro (Yao et al., 2008).

The UCH enzymes have a small highly conserved papain-like catalytic domain (CD) characterized by a flexible active site cross-over loop (CL). The CL is thought to select substrates according to leaving group size (Popp et al., 2009; Zhou et al., 2012). In UCH-L5 and UCH family member BAP1 the CL is relatively large, enabling them to process larger substrates (Zhou et al., 2012).

Within the UCH family UCH-L5 and BAP1 are close relatives. BAP1 is a critical tumor suppressor whose regulation is important for proper gene regulation (Carbone et al., 2013; Goldstein, 2011; White and Harper, 2012). UCH-L5 and BAP1 share an unusual C-terminal helical extension, called ULD (Misaghi et al., 2009). The ULD domain could mediate protein-protein interactions, including higher-order homo-oligomerization (Burgie et al., 2012; Jiao et al., 2014), and was proposed to act as an auto-inhibitory module (Yao et al., 2006).

Like UCH-L5, BAP1 can be activated by a regulatory protein, in this case ASX, to promote H2A deubiquitination (Scheuermann et al., 2010). Phylogenetic analyses have uncovered a conserved domain within the UCH regulatory proteins RPN13, INO80G, and ASX, which was named the DEUBAD domain (Sanchez-Pulido et al., 2012). As all three proteins affect UCH activity, it was proposed that the DEUBAD domain is responsible for this modulation. The conservation suggests a common mechanism of regulation, but where ASX and RPN13 activate their cognate DUB, INO80G inhibits it. Thus, the DEUBAD domain has shifted from activator to inhibitor mode. The mechanistic details of this dual mode of action of the DEUBAD domains are unclear.

Here we present structural and functional analyses that explain how DEUBAD domains can switch UCH-L5 activity and thus provide either positive or negative regulation. We show how the DEUBAD domain in RPN13 activates UCH-L5 by tuning the conformation of structural elements in UCH-L5, and inhibits in INO80G, where it exploits molecular mimicry and UCH-L5 conformational plasticity to prevent ubiquitin docking and catalysis. We also show how the inhibitory domain in INO80G has retained the ability to activate, by its N-terminal INO80G<sub>short</sub> region, and identify the structural elements in the DEUBAD domains that confer the activating or inhibitory effects on UCH-L5 enzymatic activity. Our data show that this remarkable tuning of activity involves large conformational changes and is mediated by precise positioning of both the UCH-L5 C-terminal ULD and active site CL.

## RESULTS

### Crystal Structures of Activated and Inhibited UCH-L5

To study the regulation of UCH-L5 by DEUBAD domains, we purified human UCH-L5 in complex with the DEUBAD domains of RPN13 (amino acid [aa] 265–388, referred to as RPN13<sup>DEU</sup>) and INO80G (aa 39–170, referred to as INO80G<sup>DEU</sup>) (Figure 1A). We measured the catalytic activity of these complexes towards the minimal substrate ubiquitin-7-amido-4-methylcoumarin (Ub-AMC) (Dang et al., 1998; El Oualid et al., 2010) in comparison to full-length UCH-L5 alone (U) and its isolated CD. In line with previous data, we found that the DEUBAD domain of RPN13 activates UCH-L5 (UR) (Figure 1B; Hamazaki et al., 2006; Qiu et al., 2006; Yao et al., 2006). Since the UCH-L5 CD is more active than the full-length alone, the ULD domain partially inhibits activity (Yao et al., 2006). However, in the presence of RPN13<sup>DEU</sup>, UCH-L5 is significantly more active than the UCH-L5 CD, and, therefore, RPN13<sup>DEU</sup> does more than simply remove autoinhibition (Figure 1B). Strikingly, INO80G<sup>DEU</sup> severely inhibits activity under these conditions (UI) (Figure 1B).

We wondered how these related DEUBAD domains achieve such remarkably opposite effects on regulation. To assess this, we performed structural studies on UCH-L5 in complex with DEUBAD domains and compared them with apo UCH-L5 (Burgie et al., 2012; Figure 1C). We determined a crystal structure of UCH-L5 in complex with the inhibitory domain INO80G<sup>DEU</sup> at 3.7 Å (Figure 1D). Additionally, we determined crystal structures of UCH-L5 in complex with activating RPN13<sup>DEU</sup>, with and without the suicide inhibitor ubiquitin-propargyl (Ub-Prg) (Ekkebus et al., 2013; Sommer et al., 2013) at 2.3 Å and 2.8 Å, respectively (Figures 1E and 1F). All structures were refined to acceptable statistics (Table 1).

The resulting structures display striking differences (Figures 1D–1F). Both RPN13<sup>DEU</sup> and INO80G<sup>DEU</sup> primarily bind the C-terminal ULD domain of UCH-L5, but are positioned radically differently relative to the UCH-L5 CD, which itself hardly changes conformation among all UCH-L5 structures. The differences arise from major changes in orientation of the ULDs relative to the CD (Figure 1G). The ULDs adopt a wide range of positions relative to the CD, even in previously known UCH-L5 structures (Burgie et al., 2012; Maiti et al., 2011; Morrow et al., 2013), suggesting that this element is flexible in solution. Activator and inhibitor may lock this domain in particular conformations.

To allow UCH-L5 binding, RPN13<sup>DEU</sup> changes conformation compared to the previously determined RPN13<sup>DEU</sup> apo-state (Chen et al., 2010), by rearranging core helices  $\alpha$ 1– $\alpha$ 4 and the

### Figure 1. Crystal Structures UCH-L5/DEUBAD Complexes

- Constructs used in this study.
- RPN13<sup>DEU</sup> activates UCH-L5 (UR) while INO80G<sup>DEU</sup> inhibits UCH-L5 (UI) in Ub-AMC enzyme kinetics. The CD is slightly more active than FL UCH-L5 (U). See Figure 1A for naming codes. Error bars, SD.
- Structure of apo UCH-L5 (3ihr). CD, blue; ULD domain, light blue.
- Structure of UCH-L5/INO80G<sup>DEU</sup> (INO80G<sup>DEU</sup>, orange).
- Structure of UCH-L5/RPN13<sup>DEU</sup> (RPN13<sup>DEU</sup>, green).
- Structure of UCH-L5~Ub-Prg/RPN13<sup>DEU</sup> (Ub-Prg, yellow).
- The ULDs are found in different conformations across UCH-L5 structures. The CD is transparent for clarity.
- RPN13<sup>DEU</sup> (green) changes toward an open state upon UCH-L5 complex formation compared to apo RPN13<sup>DEU</sup> (gray). Helices  $\alpha$ 1–4 and the  $\alpha$ 3–4 loop that undergo the largest changes are colored in darker shades.
- Superposition of RPN13<sup>DEU</sup> and INO80G<sup>DEU</sup>. DEUBAD domains deviate most at FRF hairpin and helix  $\alpha$ 6. See also Tables 1, S1, S2, and S4 and Figure S1.



**Table 1. Crystallography Details**

Data Collection		UCH-L5/RPN13 <sup>DEU</sup>	UCH-L5~Ub-Prg/ RPN13 <sup>DEU</sup>	UCH-L5/INO80G <sup>DEU</sup>	UCH-L5~Ub-Prg/ INO80G <sub>short</sub>
Wavelength (Å)		0.98	0.87	0.91	0.87
Resolution (Å)		33.5–2.8 (3.0–2.8)	45.3–2.3 (2.4–2.3)	47.7–3.7 (4.1–3.7)	47.7–3.7 (4.0–3.7)
Space group		P2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	P2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	P4 <sub>1</sub> 22	C2
Unit cell	a, b, c (Å)	56.6, 97.07, 100.6	59.34, 98.6, 100.2	94.88, 94.88, 132	152.1, 137.8, 98.9
	α, β, γ (°)	90, 90, 90	90, 90, 90	90, 90, 90	90, 102.5, 90
CC <sub>1/2</sub> (%)		99.8 (72.9)	99.9 (67.6)	98.3 (41.8)	98.4 (72.6)
R <sub>merge</sub> (%)		7.1 (93.0)	12.6 (83.2)	20.9 (73.2)	19.9 (66.4)
I/σI		15.3 (2.2)	9.7 (1.6)	7.4 (2.4)	5.8 (1.8)
Completeness (%)		98.5 (97.3)	99.8 (98.9)	99.5 (100)	97.9 (90.3)
Redundancy		3.9 (3.7)	4.1 (4.1)	6.7 (6.8)	4.2 (4.0)
Refinement					
Number of unique reflections		13,635	26,949	7,004	21,090
R <sub>work</sub> /R <sub>free</sub> (%)		23.2/28.4	19.5/23.5	30.4/35.4	23.8/26.6
Rmsd bond lengths (Å)		0.003	0.005	0.004	0.008
Rmsd bond angles (°)		0.7	1.0	0.7	1.2
Ramachandran statistics <sup>a</sup> (%)		99.2/0.8/0	98.5/1.5/0	97.7/2.03/0	95.02/4.98/0
(preferred/allowed/not allowed)					

High-resolution shells in parentheses.

<sup>a</sup>Molprobability.

α3-α4 loop (Figure 1H). In this new conformation, the cores of INO80G<sup>DEU</sup> and RPN13<sup>DEU</sup> resemble each other, underscoring their common ancestry (Figures 1I and S1A). The C termini of the DEUBAD domains, however, diverge dramatically. Where helices α6–α8 (aa 350–384) form a platform in RPN13<sup>DEU</sup>, the equivalent region in INO80G<sup>DEU</sup> forms a single extended helix (α6). Another notable difference between the two DEUBAD domains is a short hairpin (aa 96–103) exclusively present in INO80G, which we named the FRF hairpin. It is inserted between helix α4 and α5 of the DEUBAD domain and is conserved in INO80G orthologs (Figures 1I and S1B).

The structural conservation of the DEUBAD domains is also reflected in their similar binding modes to UCH-L5 (Figures 1D–1F and S1C). In both complexes, the core DEUBAD domains bind primarily to the C-terminal ULD of UCH-L5, where amphipathic helix α11 is clasped by the DEUBAD domains and further stabilized by helix α12 in an extensive hydrophobic interface (Figures S1D and S1E). DEUBAD domain binding requires these helices, since a UCH-L5 variant lacking these (UCH-L5<sub>Δα11-12</sub>) does not interact with RPN13<sup>DEU</sup>, whereas the wild-type (WT) UCH-L5 binds tightly ( $K_D = 6$  nM) in isothermal titration calorimetry (ITC) (Figure S1F; Table S4).

In short, the conserved DEUBAD domains bind to UCH-L5 but show dramatically different arrangements. In the next sections, we examine how these are achieved and how they can lead to differences in UCH-L5 activity. The structural consequences of ubiquitin binding are discussed in light of the mechanism of activation and inhibition.

### DEUBAD Domains Tune UCH-L5 Substrate Affinity


Analysis of UCH-L5 kinetic parameters (Figure 1B; Table S1) reveals that RPN13<sup>DEU</sup> binding primarily changes the  $K_M$  of the

enzyme, but hardly affects  $k_{cat}$ . Therefore, we wondered if changes in substrate affinity of UCH-L5 could explain regulation by DEUBAD domains.

We assessed the ability of UCH-L5 to bind a model substrate in the presence and absence of the DEUBAD domains using ITC. The model substrate Ub-GlySerThr was titrated into active site cysteine (C88A) mutants of the different UCH-L5 complexes. We observed robust binding ( $K_D = 4.5$  μM) for UCH-L5/RPN13<sup>DEU</sup>, whereas binding to UCH-L5 alone, UCH-L5 CD, and UCH-L5/INO80G<sup>DEU</sup> did not reach saturation, with the UCH-L5/INO80G<sup>DEU</sup> complex giving the lowest signal (Figures 2A and S2A; Table S3). These results suggest that RPN13<sup>DEU</sup> enhances UCH-L5 substrate binding, whereas INO80G<sup>DEU</sup> diminishes it. We validated these results in fluorescence polarization (FP) binding assays, using Ub-LysGly<sup>TAMRA</sup> as a model substrate (Geurink et al., 2012), which confirmed that DEUBAD domains tune UCH-L5 activity at the level of substrate binding (Figure 2B).

### Ubiquitin Binding by the UCH-L5/RPN13<sup>DEU</sup> Complex

UCH-L5 activation by the RPN13 DEUBAD domain results from enhanced ubiquitin-substrate binding; therefore, we analyzed the details of ubiquitin interaction in the UCH-L5~UbPrg/RPN13<sup>DEU</sup> crystal structure (Figure 2C). The presence of Ub-Prg hardly changed the global UCH-L5/RPN13<sup>DEU</sup> conformation (Figure 1). Direct contact between ubiquitin and RPN13<sup>DEU</sup> involved a small interface (286 Å<sup>2</sup>) with three hydrogen bonds (Figures 2C and 2D). Moreover, this interface did not affect the position and orientation of ubiquitin on UCH-L5, which resembled the previously solved *T. spiralis* UCH-L5 ubiquitin complex. In fact, it was identical to the canonical ubiquitin-binding mode found in all UCH family members (Figure 2E).



**Figure 2. Ubiquitin Binding of UCH-L5 Complexes**

(A) RPN13<sup>DEU</sup> increases UCH-L5's affinity for model substrate Ub-GlySerThr, whereas INO80G<sup>DEU</sup> decreases the signal in ITC.

(B) Validation of binding results using model substrate Ub-LysGly<sup>TAMRA</sup> in FP binding assays. Error bars, SD.

(C) Overview of the ubiquitin-binding interface of the UCH-L5~Ub-Prg/RPN13<sup>DEU</sup> complex.

(D) Contacts between ubiquitin and RPN13<sup>DEU</sup> are limited.

(E) Ubiquitin binding in the UCH family is structurally conserved (UCH-L5/RPN13<sup>DEU</sup>; *T. spiralis* UCH-L5, 4i6n; UCH-L1, 3ifw; UCH-L3, 1xd3; *P. falciparum* UCH-L3, 2wdt).

(F) The ubiquitin tail is extensively coordinated.

(G) The ubiquitin core is stabilized by three specific exosite contacts. UCH-L5/RPN13<sup>DEU</sup> (without Ub-Prg) displayed in gray sticks.

(H) Partial melting of UCH-L5 helix  $\alpha 8$  relocates Ile216 to contact the ubiquitin Ile36 patch. This interaction is conserved in *T. spiralis* UCH-L5. See also Table S3 and Figure S2B.

In practice, ubiquitin binds via its C-terminal tail close to the active site and via its core relatively far from the active site, in a series of so-called exosites. In the UCH-L5 complex, the ubiquitin C-terminal tail adopts an extended conformation. It is buried and positioned by an extensive network of side-chain and backbone interactions with the CD (Figures 2C and 2F).

The binding of the ubiquitin core creates three specific exosite interactions on the UCH-L5 CD. The first involves UCH-L5 Trp36, which rearranges, compared to apo UCH-L5/RPN13<sup>DEU</sup>, to avoid clashes and to promote a direct contact with ubiquitin Ile44 (Figures 2C and 2G), the primary hydrophobic binding site on ubiquitin.

A second exosite interaction involves UCH-L5 Ile216 at the C terminus of helix  $\alpha 8$  (Figure 2G). This helix melts out in UCH-ubiquitin complexes, but is extended in the absence of ubiquitin (Figure S2B). Partial melting of  $\alpha 8$  is crucial since it rearranges Ile216 from a buried position to a position in the  $\alpha 8$ - $\beta 6$  connecting loop that is compatible with ubiquitin binding, similar to *T. spiralis* UCH-L5 where Val214 (equivalent to human Ile216) contacts the ubiquitin Ile36 patch (Morrow et al., 2013; Figure 2H). Interestingly, in the UCH-L5/RPN13<sup>DEU</sup> structure, the C terminus of helix  $\alpha 8$  is already disordered in the absence of ubiquitin, indicating that RPN13<sup>DEU</sup> may affect this region allosterically to facilitate ubiquitin binding.

Finally, the melting of helix  $\alpha 8$  and ordering of the  $\alpha 8$ - $\beta 6$  connecting loop promotes positioning of Phe218 and formation of a highly conserved pocket that includes UCH-L5 Leu38. This hydrophobic pocket on UCH-L5 allows a snug interaction with the ubiquitin  $\beta 1$ - $\beta 2$  hairpin containing Leu8 and Thr9 (Figure 2G). Formation of this pocket was described for UCH-L1, upon ubiquitin interaction (Boudreaux et al., 2010). In UCH-L1 the Phe214 positioning promotes rearrangement of Phe53 (equivalent to UCH-L5 residues, Phe218 and Phe56), which is necessary to organize the catalytic site conformation. In UCH-L5 this relay is not required, since Phe56 is already positioned such that the catalytic triad is active in the apo-structure. Nevertheless, the conformational change of UCH-L5 Phe218 in this pocket is conserved upon ubiquitin binding, as is the interaction with the ubiquitin  $\beta 1$ - $\beta 2$  hairpin. All three exosite interactions are well conserved in the UCH family, explaining the remarkably similar ubiquitin positioning on the UCH CDs (Figure 2E).

### The DEUBAD Domain of RPN13 Activates UCH-L5 by ULD and CL Positioning

To investigate how RPN13<sup>DEU</sup> promotes enhanced substrate binding by UCH-L5, we tested the effect of mutations on activity. We first focused on the effect on activation of the ubiquitin-binding residues in UCH-L5. Mutations in these residues lowered the activity substantially, irrespective of the presence of RPN13<sup>DEU</sup>, indicating that they are primarily important for basic DUB function (Figure 3A). We then tested mutations of RPN13<sup>DEU</sup> located in the interface with ubiquitin, and found that these provided only a limited contribution to UCH-L5 activation (Figures 2D and S2C).

To further explore the molecular origins of the activation, we analyzed the evolutionary conservation of surface residues on UCH-L5 with ConSurf (Glaser et al., 2003). A UCH-L5 sequence alignment from species across all major eukaryotic lineages that possess both RPN13 and UCH-L5 was projected onto the UCH-L5 structure. This was compared to an analogous conservation analysis for UCH-L3, a prototype UCH member that lacks the C-terminal ULD domain. We noted several conserved regions. Both UCHs have a conserved surface patch where ubiquitin binds (Figure 3B). Adjacent to this patch, we found a second highly conserved site in UCH-L5 orthologs that is absent in UCH-L3 orthologs. This site centers on Glu283 and anchors the ULD to the CD through a polar interaction network (Figure 3C). The strong conservation of this ULD anchor is intriguing as the area is not directly involved in ubiquitin or RPN13<sup>DEU</sup> binding.

We assessed the functional importance of the ULD anchor by testing UCH-L5 mutants in Ub-AMC assays. UCH-L5<sup>E283A</sup> had similar activity to WT but this mutant could not be activated to the same extent as WT by RPN13<sup>DEU</sup>, mainly due to weaker  $K_M$  (Figure 3D; Tables S1 and S2). The fact that this E283A mutation does not affect intrinsic UCH-L5 activity, but only the activity of the RPN13<sup>DEU</sup> complex, strongly suggests that an intact ULD anchor is required for RPN13<sup>DEU</sup>-dependent activation of UCH-L5. Next we tested the effect of E283A mutation on substrate binding. Using ITC and stopped-flow binding analysis, we found that UCH-L5<sup>E283A</sup>/RPN13<sup>DEU</sup> shows decreased affinity for Ub substrates compared to WT complex (Figures S2A and S2D; Table S3). This indicates that RPN13<sup>DEU</sup> induces a higher affinity for substrates by utilizing the intact ULD anchor.


We then focused our attention on the UCH-L5 CL that is disordered in most UCH-L5 crystal structures. In our complexes, the CL makes contacts with RPN13<sup>DEU</sup> (Figure 3E) via the highly conserved Met148 and Phe149, partially ordering the loop. Given the importance of the CL for the ability of UCHs to process larger substrates (Popp et al., 2009; Zhou et al., 2012), we made mutants to test whether the interface of the CL with RPN13<sup>DEU</sup> could affect activity by positioning the loop. In a Ub-AMC assay, UCH-L5<sup>M148A/F149A</sup> hydrolyzed Ub-AMC comparable to WT, indicating that the mutant was still functional. However, this mutant was only marginally activated by the addition of RPN13<sup>DEU</sup> (2.7-fold instead of 7-fold in WT), indicating that UCH-L5 activation by RPN13<sup>DEU</sup> requires an intact CL (Figure 3F; Tables S1 and S2). Interestingly, unlike the ULD anchor mutant, the CL mutant and WT complexes bound model substrates with similar affinities (Figures S2A and S2D; Table S3).

Combining the CL and ULD anchor mutants into UCH-L5<sup>double</sup> resulted in an almost complete abrogation of RPN13<sup>DEU</sup>-mediated activation, illustrating that the CL and ULD anchor are the principal regulatory sites used by RPN13<sup>DEU</sup> (Figure 3G). As none of the UCH-L5 mutants were compromised in RPN13<sup>DEU</sup> binding, as shown by ITC (Figure S2E; Table S4), we conclude that RPN13<sup>DEU</sup> exerts its stimulatory effect on UCH-L5 through positioning of the CL and ULD anchor.

### Mechanism of UCH-L5 Inhibition by INO80G<sup>DEU</sup>

Our binding assays showed that INO80G<sup>DEU</sup> decreases the affinity of UCH-L5 for substrates (Figures 2A and 2B). To understand this effect, we analyzed how INO80G<sup>DEU</sup> affects UCH-L5 conformation (Figure 1) in more detail. INO80G<sup>DEU</sup> alters the ULD domain's relative position and conformation in two specific ways. First, helix  $\alpha 9$  and  $\alpha 10$  are tilted by  $\sim 30^\circ$  compared to the active ULD conformation, and, second, the C-terminal end of helix  $\alpha 10$  is bent toward the CD (Figure 4A). As a result, sections of the ULD and INO80G<sup>DEU</sup> occupy the canonical ubiquitin-binding exosites on UCH-L5 and thus prevent substrate docking (Figure 4A). The blockage of the exosites by the INO80G<sup>DEU</sup> complex presents a structural rationale for the decreased substrate binding that we observed, and provides a simple yet unexpectedly striking explanation of the INO80G<sup>DEU</sup> inhibition mechanism.

Analysis of the UCH-L5/INO80G<sup>DEU</sup> interface shows how the large conformational changes in UCH-L5 organize novel interfaces where key elements for ubiquitin binding and RPN13<sup>DEU</sup>-mediated activation are exploited by INO80G<sup>DEU</sup> to inhibit



**Figure 3. Activation Mechanism RPN13<sup>DEU</sup>**

(A) Mutations in the ubiquitin interface severely compromise DUB activity irrespective of RPN13<sup>DEU</sup> (top). Location mutants (yellow sticks) on UCH-L5 (bottom). (B) Surface representation of UCH-L3 and UCH-L5 colored by conservation. (C) UCH-L5 helix  $\alpha 10$  is anchored to the CD via an extensive polar network. (D and F) Compared to WT (UR and U from Figure 1B), UCH-L5 mutants E283A and M148A/F149A cannot be activated by RPN13<sup>DEU</sup> to the same extent on Ub-AMC. Error bars, SD. (E) The CL is positioned by RPN13<sup>DEU</sup>. (G) Activation of the combined CL and ubiquitin anchor mutants E283A/M148A/F149A is almost completely abrogated compared to WT (UR and U from Figure 1B). Error bars, SD. See also Figure S2 and Tables S1–S4.


UCH-L5 activity. First, ULD conformational changes allow INO80G<sup>DEU</sup> helix  $\alpha 6$  to contact the UCH-L5 CD, possibly stabilizing the inhibitory conformation of the ULD (Figures 1D and S1D). Second, in a neat example of molecular mimicry, the INO80G FRF hairpin binds to the UCH-L5 Leu38 pocket in a fashion that resembles the binding of the structurally analogous ubiquitin  $\beta 1$ - $\beta 2$  hairpin to this pocket (Figures 4B and 4C). Next, the C terminus of UCH-L5 helix  $\alpha 8$  refolds to make the extra helical turn seen in the apo-structure. As a result, UCH-L5 Ile216 rearranges toward the hydrophobic core, preventing the possibility of the important interaction with the ubiquitin Ile36 patch (Figure 4D). Finally, helix  $\alpha 10$  bending in the INO80G<sup>DEU</sup> complex relocates the ULD anchor residues toward UCH-L5 Trp36, creating a novel intramolecular interface consisting of a cation- $\pi$  stacking interaction between the indole ring of the Trp36 and Arg287 in UCH-L5 helix  $\alpha 10$  (Figure 4E). This relocation simultaneously precludes Trp36 availability for ubiquitin

binding and impedes the formation of the intricate polar interaction network in the ULD anchor that is required for UCH-L5 activation by RPN13<sup>DEU</sup> (Figure 3C). Thus, all elements for ubiquitin binding in UCH-L5 are effectively obscured by INO80G<sup>DEU</sup> binding.

### The FRF Hairpin Creates the Activity Switch in DEUBAD Domains

To study what features in INO80G<sup>DEU</sup> are required to achieve UCH-L5 inhibition, we analyzed its differences with the activating DEUBAD domain of RPN13. The most striking difference between the DEUBAD domains of RPN13 and INO80G is the C-terminal part where three helices  $\alpha 6$ - $\alpha 8$  in RPN13<sup>DEU</sup> change to the extended  $\alpha 6$  in INO80G<sup>DEU</sup> that packs against the CD (Figures 5A and S1D). Therefore, we created a shorter version of INO80G<sup>DEU</sup>, where helix  $\alpha 6$  is removed (Figure 1A, residues 39–118, INO80G<sup>DEU</sup> <sub>$\Delta\alpha 6$</sub> ). Surprisingly, the truncated protein





**Figure 4. Inhibition Mechanism INO80G<sup>DEU</sup>**

(A) The ubiquitin-docking site on UCH-L5 is blocked as a result of INO80G<sup>DEU</sup>-induced conformational changes of the ULD. RPN13<sup>DEU</sup> is removed for clarity.

(B and C) The FRF hairpin mimics the ubiquitin  $\beta$ 1- $\beta$ 2 hairpin to bind the Leu38 pocket.

(D) In contrast to the activated state, helix  $\alpha$ 8 in UCH-L5 adopts an extended state in the INO80G<sup>DEU</sup> complex to bury Ile216.

(E) The ULD anchor interaction is disrupted in the INO80G<sup>DEU</sup> complex due to ULD tilting and helix  $\alpha$ 10 bending, establishing intramolecular stacking of Arg287 on Trp36.


INO80G<sup>DEU</sup> <sub>$\Delta\alpha 6$</sub>  still inhibited UCH-L5 (Figure 5B), demonstrating that helix  $\alpha$ 6 is not required for inhibition under these conditions.

We next assessed the importance of the INO80G FRF hairpin, which is the other major structural difference between the RPN13<sup>DEU</sup> and INO80G<sup>DEU</sup> (Figures 1I and 5A). In the hairpin, the side chain of the highly conserved Phe100 (Figure S1B) is accommodated by the UCH-L5 Leu38 pocket (Figure 4C), suggesting that this interaction is important for INO80G function. To address the relevance of this interaction, we made a single-point mutant F100A in INO80G<sup>DEU</sup>.

This point mutant, INO80G<sup>DEU</sup><sub>F100A</sub>, lost the ability to inhibit UCH-L5 in Ub-AMC assays. In fact, it restored activity to the level of UCH-L5 alone, highlighting the importance of the FRF-hairpin interaction for UCH-L5 inhibition (Figure 5C; Tables S1 and S2). Moreover, the F100A complex gained a significant substrate-binding ability in contrast to the WT INO80G<sup>DEU</sup> complex (Figure 5D). Loss of the phenylalanine interaction makes the Leu38 pocket available again for binding of the

$\beta$ 1- $\beta$ 2 hairpin of ubiquitin (Figure 2G), but most likely also allows helix  $\alpha$ 10 to revert to its extended state, affecting the ULD position.

The structural changes in the DEUBAD domains may have been a crucial evolutionary event facilitating novel regulatory modes of the DEUBAD domain. To test this we created a chimeric RPN13<sup>DEU</sup> variant (RPN13<sup>DEU</sup><sub>chimera</sub>) by inserting the INO80G FRF hairpin into the structurally equivalent position in RPN13<sup>DEU</sup> (Figure S3A). The chimera formed a stable complex with UCH-L5 (Figure S3B), but completely abolished the activation effect. The inserted FRF hairpin was not sufficient to inhibit UCH-L5 to the same extent as INO80G<sup>DEU</sup> however (Figure 5E; Table S1). In RPN13<sup>DEU</sup><sub>chimera</sub> the presence of the FRF hairpin likely diminishes ubiquitin binding, as it would be overlapping with the ubiquitin-binding site explaining the loss of activation potential. These results demonstrate that the FRF hairpin and its location within the DEUBAD domain have a crucial effect on UCH-L5 activity.



**Figure 5. The FRF Hairpin Drives UCH-L5 Inhibition**

(A) INO80G<sup>DEU</sup> differs from RPN13<sup>DEU</sup> mainly in the FRF hairpin and helix  $\alpha 6$  (orange surfaces).

(B) Helix  $\alpha 6$  of INO80G<sup>DEU</sup> is dispensable for inhibition in Ub-AMC assays. Error bars, SD.

(C) Inhibition is completely lost in the INO80G<sup>DEU</sup> F100A mutant (UI<sub>F100A</sub>) on Ub-AMC. Error bars, SD.

(D) Mutant complex F100A gains Ub-GlySerThr-binding ability compared to WT INO80G<sup>DEU</sup> complex (from Figure 3A) in ITC.

(E) Insertion of the FRF hairpin in RPN13<sup>DEU</sup> chimera abolishes the activation effect of WT RPN13<sup>DEU</sup> on UCH-L5 (UR and U from Figure 1B). Error bars, SD. See also Figure S3 and Tables S1–S3.

### The INO80G<sub>short</sub> Activation Mechanism Also Relies on ULD Positioning

We wondered how lack of the FRF hairpin would affect the structure of UCH-L5 and INO80G. To this end, we determined the 3.7 Å structure of UCH-L5 in complex with Ub-Prg and INO80G<sub>short</sub> (aa 39–101), a shorter fragment of INO80G<sup>DEU</sup> (Figure 1A). The artificial INO80G<sub>short</sub> construct has the remarkable capability to activate UCH-L5 in vitro (Yao et al., 2008). INO80G<sub>short</sub> starts at the same residue as INO80G<sup>DEU</sup> but terminates in the middle of the FRF hairpin and, hence, is predicted not to contain a folded FRF hairpin. Indeed, in the crystal structure, the C-terminal end of INO80G<sub>short</sub> could not be unambiguously modeled, indicating that the FRF hairpin is not formed in this complex.

Strikingly, the UCH-L5~UbPrg/INO80G<sub>short</sub> crystal structure resembled the activated RPN13<sup>DEU</sup> complex rather than the inhibited state (Figures 6A, S4A, and S4B). In this complex, the ULD largely reverted to the conformation seen in the activated RPN13<sup>DEU</sup> complexes with an extended helix  $\alpha 10$  (Figure S4C). All conformational changes in UCH-L5 required to create the canonical ubiquitin-binding mode were also in place (Figures S4D and S4E). The structure of INO80G<sub>short</sub> itself and its binding mode to UCH-L5 were moreover identical to INO80G<sup>DEU</sup> (apart from FRF hairpin and  $\alpha 5$ –6) and RPN13<sup>DEU</sup> (Figure S4F).

Enzyme kinetics analysis confirmed that INO80G<sub>short</sub> activates UCH-L5 on Ub-AMC (Figure 6B). The activation effect correlates with increased affinity for substrates, since UCH-L5 binds substrates better in the presence of INO80G<sub>short</sub> in ITC-binding assays (Figure 6C). These results stress that DEUBAD domains mainly modulate activity by tuning substrate affinity.


The similarity in structure to the RPN13<sup>DEU</sup> complex suggests that INO80G<sub>short</sub> makes use of the same activation mechanism.

To test this hypothesis, we used the UCH-L5<sub>E283A</sub> ULD anchor mutant, asking whether loss of the ULD anchor would also affect the activation in this case. We found that the UCH-L5<sub>E283A</sub>/INO80G<sub>short</sub> mutant complex was compromised in Ub-AMC hydrolysis (Figure 6B; Tables S1 and S2), reverting to the activity observed for UCH-L5 alone. This finding indicates the importance of the ULD anchor (Figure 6D) for INO80G<sub>short</sub> activation, and it suggests that ULD positioning in general is a major feature of the activation. INO80G<sub>short</sub>, containing only the helices  $\alpha 2$ – $\alpha 4$  of the DEUBAD domain, can activate UCH-L5, demonstrating that the core DEUBAD fold is already sufficient to bind and provide modest activation. The INO80G<sub>short</sub> complex does not attain UCH-L5/RPN13<sup>DEU</sup> activity levels however. Most likely this is because it lacks helix  $\alpha 5$ , which RPN13<sup>DEU</sup> uses to position the CL (Figure S4G).

Collectively, the UCH-L5/INO80G<sub>short</sub> structure analysis reconciled all our previous findings. First, it confirmed that the FRF hairpin is the crucial factor for inhibition, since absence of this element resulted in loss of inhibition. Second, loss of the FRF hairpin destabilized the inhibitory ULD conformation, causing it to snap back to a substrate-binding-competent conformation. Third, the core DEUBAD fold was sufficient to provide the basic UCH-L5 activation function. Like RPN13 it executed activation by stabilizing the substrate-binding-competent conformation of the ULD through the ULD anchor.

### DISCUSSION

Our data show how UCH-L5 activity can be modulated by DEUBAD domains present in RPN13 and INO80G through remarkably large conformational changes. Functionally, the activity of UCH-L5 is tuned at the level of substrate affinities, where



**Figure 6. Reactivation of the Inhibitor and Model for UCH-L5 Regulation**

(A) The crystal structure of UCH-L5~Ub-Prg/INO80G<sub>short</sub> (middle) largely resembles the UCH-L5/RPN13<sup>DEU</sup> structures (left from Figure 1F), but not the UCH-L5/INO80G<sup>DEU</sup> structure (right from Figure 1D).

(legend continued on next page)



RPN13<sup>DEU</sup> increases the affinity for substrates and INO80G<sup>DEU</sup> dramatically decreases substrate affinity. Our structural and biochemical analyses indicate that RPN13<sup>DEU</sup> achieves this effect by precise positioning of the ULD anchor and CL. The direct contact between RPN13<sup>DEU</sup> and ubiquitin furthermore confers a mild activation effect on UCH-L5 by stabilizing ubiquitin. Conversely, INO80G<sup>DEU</sup> exploits molecular mimicry and ULD conformational plasticity to prevent ubiquitin docking and catalysis. We showed which structural changes in DEUBAD domains may have been instrumental for the evolution of different modes of UCH-L5 regulation.

The proposed evolutionary conservation of the DEUBAD domains (Sanchez-Pulido et al., 2012) was confirmed by structural analyses in this study. The DEUBAD domains appear to be modular. The core DEUBAD fold ( $\alpha 1$ – $\alpha 4$ ) is shared among INO80G<sup>DEU</sup>, RPN13<sup>DEU</sup>, and INO80G<sub>short</sub>, and is responsible for binding to UCH-L5 and modest activation. Accessory structural modules in RPN13<sup>DEU</sup> (helix  $\alpha 5$  that positions the CL) and INO80G<sup>DEU</sup> (FRF hairpin) lead to full activation or inhibition of UCH-L5. The modular nature of the DEUBAD domains explains their versatility as regulatory domains.

A key feature of UCH-L5 activity modulation is the conformational plasticity of the ULD that is found in a variety of conformations in the available UCH-L5 crystal structures (Figure 1G). This plasticity and the current data are consistent with a model where the UCH-L5 ULD can adopt a multitude of possible conformations in a dynamic fashion when free in solution (Figure 6E). As a consequence of the ULD's proximity to the ubiquitin docking site, some of these conformations are sterically incompatible with ubiquitin binding while others allow efficient ubiquitin binding. The DEUBAD domain in RPN13<sup>DEU</sup> and INO80G<sup>DEU</sup> restricts ULD conformational plasticity by preferentially stabilizing specific conformations. RPN13<sup>DEU</sup> activates and increases the affinity for substrates by fixing the ULD into a substrate-binding-competent conformation, using the ULD anchor. Additionally, full activation is achieved by the stabilization of the ubiquitin orientation by RPN13<sup>DEU</sup> and correct positioning of the CL. On the other hand, INO80G<sup>DEU</sup> binds to UCH-L5 and uses ULD conformational flexibility to dock its unique inhibitory FRF hairpin into the Leu38 pocket. This interaction fixes the ULD in such a way that the ubiquitin-binding site is blocked by INO80G<sup>DEU</sup> and the ULD. In the process, key molecular elements for ubiquitin binding and RPN13-dependent activation are masked or disrupted, effectively inhibiting activity.

This regulatory model may co-exist with possible roles of the UCH-L5 oligomeric state for regulation of its activity (Burgie et al., 2012; Jiao et al., 2014; Yao et al., 2006). As the enzyme concentrations under our assay conditions were low, it is unlikely that we captured these phenomena. However, we cannot

exclude that additional layers of regulatory complexity may exist in cells that involve UCH-L5 oligomeric states.

Our structures of UCH-L5/RPN13<sup>DEU</sup> explain the basic mechanisms of activation by the RPN13 DEUBAD module. It will be interesting to investigate the additional activation that is required to hydrolyze K48-polyubiquitin in the proteasomal 19S regulatory particle. It is conceivable that efficient K48-polyubiquitin hydrolysis will only take place after steps that are possibly related to proper positioning and unfolding of the compact K48-polyubiquitin chains. A key step here will be the identification of the minimal proteasomal complex required to perform chain hydrolysis.

The UCH-L5/INO80G<sup>DEU</sup> structure may provide novel approaches in unraveling the enigmatic role of UCH-L5 and INO80G in INO80 chromatin-remodeling complexes. INO80G is a key factor in embryonic stem cells and knock out leads to loss of pluripotency (Wang et al., 2014). Of specific interest is why UCH-L5 is kept in an inhibited state in the INO80 complex (Yao et al., 2008). A possibility is that INO80 controls UCH-L5 in a temporal manner, where in some circumstances UCH-L5 is inhibited while under other circumstances post-translational modifications (PTMs) and/or conformational changes release the inhibition and activate UCH-L5, allowing for additional layers of regulation. We have already seen in INO80G<sub>short</sub> that the core DEUBAD fold has the intrinsic ability to activate UCH-L5 and all that is required for INO80G<sup>DEU</sup> to relieve inhibition is disruption of the FRF hairpin. Such relief of inhibition would be important for the recently reported UCH-L5/INO80G role in DNA double-strand-break response, since UCH-L5 catalytic activity is required for proper DNA end resection (Nishi et al., 2014).

A unique element of the INO80G<sup>DEU</sup> domain is the extended helix  $\alpha 6$ . This helix packs against the CD close to the active site and, therefore, initially was thought by us to confer INO80G<sup>DEU</sup> inhibitory function. In our in vitro assays, this element was dispensable for inhibition, but this may be different in a cellular context where the additional contacts between this helix and the CD may further stabilize the inactivated state. An interesting feature of helix  $\alpha 6$  is the presence of a large solvent-exposed positively charged patch. We speculate that this patch may be important in cells as a binding platform for INO80 chromatin-remodeling factors. As the equivalent region in RPN13<sup>DEU</sup> folds into a helical platform, it also may be possible that, under some conditions, driven by PTMs for example,  $\alpha 6$  could refold into a conformation seen in RPN13 to meet functional requirements. DUB activity regulation by PTMs such as phosphorylation have been shown previously to be important for DUBA (Huang et al., 2012).

The ULD is conserved in UCH family member BAP1 that is activated by the ASXL1 DEUBAD domain to deubiquitinate H2A (Scheuermann et al., 2010). Because of the strong conservation of key elements between UCH-L5/RPN13<sup>DEU</sup> and

(B) INO80G<sub>short</sub> (U<sub>short</sub>) can activate UCH-L5, albeit not to RPN13<sup>DEU</sup> levels (UR, UI, and U from Figure 1B), and depends on the ULD anchor for activation on Ub-AMC. Error bars, SD.

(C) Activation by INO80G<sub>short</sub> correlates with enhanced Ub-GlySerThr binding in ITC compared to WT UCH-L5 (from Figure 3A).

(D) The ULD anchors in the INO80G<sub>short</sub> (light blue) and RPN13<sup>DEU</sup> (gray) superimpose very well and stabilize the same intramolecular interaction.

(E) Unmodulated UCH-L5 (middle) is characterized by CL and ULD flexibility that limits substrate binding and catalysis. Activation by RPN13<sup>DEU</sup> (left) limits flexibility by locking the ULD and CL in favorable conformations. INO80G<sup>DEU</sup> (right) locks the ULD in a conformation incompatible with substrate docking. See also Figure S4 and Tables S1–S3.



BAP1/ASXL1, we anticipate that the ASXL1 DEUBAD domain employs similar strategies to activate BAP1. Both BAP1 and ASXL1 are important cancer drivers. BAP1 is a key tumor suppressor that is mutated in a number of cancers where loss of BAP1 is associated with poor prognosis and tumor aggressiveness (Carbone et al., 2013; White and Harper, 2012). Our crystal structures have valuable implications for BAP1 function in its cellular roles and pathogenesis.

The mechanisms of DUB regulation that we have described are different from those in previously studied DUB regulators. UAF1 increases the basicity of the USP1 catalytic histidine, increasing its potency as a general base (Villamil et al., 2012). Likewise, incorporation of Ubp8 in the SAGA complex stabilizes the catalytic center, also facilitating catalysis (Köhler et al., 2010; Samara et al., 2010). Activation of USP7 by GMPS against a minimal substrate changes only  $k_{\text{cat}}$  (Faesen et al., 2011). All of these differ from UCH-L5 where a major part of the activity modulation involves tuning substrate affinities, rather than actual catalytic steps.

Whereas inhibition of DUBs by proteins is still a rare phenomenon, inhibition of general proteases by proteins has been well described (Dubin, 2005; Rzychon et al., 2004). Serpins inhibit serine proteases by irreversibly trapping the acyl-enzyme intermediate. Additionally, general cysteine proteases can be inhibited by cystatins and related proteins by occupying active site clefts. Instead, INO80G functions as an exosite inhibitor where not the active site cleft but an exosite, in this case the ubiquitin-core-docking site, is blocked. Enzyme exosite targeting by a naturally evolved inhibitor could provide powerful clues about the most efficient way for DUB inhibition, and may thus be promising from a pharmaceutical perspective.

## EXPERIMENTAL PROCEDURES

### Plasmids and Cloning

Human UCH-L5, RPN13, and INO80G cDNA were subcloned from the HAP1 cell line. RPN13<sup>DEU</sup> chimera was purchased as a synthetic construct. All constructs were cloned into the pGEX or pET bacterial expression vectors of the NKI LIC suite (Luna-Vargas et al., 2011).

### Protein Expression and Purification

All protein variants and protein complexes were (co-) expressed in *E. coli*. UCH-L5 and variants were purified using glutathione S-transferase (GST) affinity purification (GSH 4B sepharose, GE Healthcare) followed by a desalting (HiPrep 26/10, GE Healthcare) and final size-exclusion chromatography step (Superdex S200, GE Healthcare). UCH-L5 complexes were purified similarly except for an additional first nickel purification step. RPN13<sup>DEU</sup> alone was expressed in *E. coli* and purified using nickel affinity chromatography, desalting, and size-exclusion chromatography (Superdex S75, GE Healthcare).

### Ub-AMC Enzymatic Assays

Enzyme activity was followed as release of fluorescent AMC from the quenched Ub-AMC substrate, providing a direct readout of DUB activity. Michaelis-Menten parameters were determined using 1 nM enzyme while varying the substrate concentration. Initial rates were plotted against substrate concentration and fitted to the Michaelis-Menten model using non-linear regression in Prism 6. In single-concentration experiments, 1 nM enzyme was allowed to react with 1  $\mu$ M substrate. Activity was quantified by calculating the initial rates.

### FP Binding Assays

Binding assays between UCH-L5 complexes and model substrate Ub-LysGly<sup>TAMRA</sup> were performed by measuring FP. Model substrate (5 nM) was

incubated at 25°C with varying amounts of different UCH-L5 complexes to obtain binding curves. To prevent substrate hydrolysis, inactive C88A mutants of UCH-L5 were used.

### Stopped-Flow Fluorescent Polarization Binding Assay

Pre-steady-state binding events between UCH-L5 (C88A) complexes and Ub-LysGly<sup>TAMRA</sup> were monitored in stopped-flow fluorescent polarization experiments. Varying concentrations of UCH-L5 variants were injected together with 20 nM (final concentration) Ub-KG<sup>TAMRA</sup>, after which fluorescent polarization was followed during 10 s. Association binding traces were fitted to a one-phase exponential model in Prism 6 to obtain  $k_{\text{obs}}$ . The  $k_{\text{obs}}$  values were plotted against protein concentration to estimate  $k_{\text{on}}$ ,  $k_{\text{off}}$ , and  $K_D$ .

### ITC

ITC experiments were performed in a VP-ITC Microcal calorimeter at 25°C. In 10  $\mu$ l injections, 450  $\mu$ M UbGlySerThr was titrated into 45  $\mu$ M UCH-L5 (C88A) or 110  $\mu$ M UCH-L5 into 12.5  $\mu$ M RPN13<sup>DEU</sup>. Data were fitted to a one-site-binding model with the manufacturer's Origin software.

### Structure Determination

Data collection was done at the European Synchrotron Radiation Facility and Swiss Light Source at 100K. Images were integrated with XDS (Kabsch, 2010) and merged/scaled with Aimless (Evans and Murshudov, 2013), followed by molecular replacement with Phaser (McCoy et al., 2007). Model refinement was carried out by Phenix (Adams et al., 2010), autoBUSTER (Smart et al., 2012), and Refmac (Murshudov et al., 1997), and models were built using COOT (Emsley et al., 2010). All structure figures were generated using PyMOL.

### ACCESSION NUMBERS

The Protein Data Bank accession number for UCH-L5/RPN13<sup>DEU</sup> is 4UEM, for UCH-L5~Ub/RPN13<sup>DEU</sup> is 4UEL, for UCH-L5/INO80G<sup>DEU</sup> is 4UF5, and for UCH-L5~Ub/INO80G<sup>short</sup> is 4UF6.

### SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, four figures, and four tables and can be found with this article online at <http://dx.doi.org/10.1016/j.molcel.2014.12.039>.

### AUTHOR CONTRIBUTIONS

D.D.S. designed, performed, and analyzed all experiments and wrote the manuscript. W.J.v.D. and D.D.S. expressed and purified proteins. F.E.O. and R.E. performed ubiquitin-conjugate synthesis. H.O. supervised ubiquitin-conjugate research. T.K.S. supervised and designed research and wrote manuscript. All authors critically read the manuscript.

### ACKNOWLEDGMENTS

We thank B8 members and Haico van Attikum for discussion and critical reading of the manuscript. We thank Marcello Clerici and Flora Groothuizen for advice in structure determination, Tatjana Heidebrecht for assistance in crystal harvesting, Vincent Blomen and Thijn Brummelkamp for the HAP1 cDNA library, Paul Geurink for Ub-LysGly<sup>TAMRA</sup>, and beamline scientists at Swiss Light Source and European Synchrotron Radiation Facility for data collection assistance. This work was supported by European Research Council advanced grant 249997 and Netherlands Organization for Scientific Research ECHO 700.59.009. H.O. and F.E.O. are cofounders and shareholders of UbiQ.

Received: October 3, 2014

Revised: November 16, 2014

Accepted: December 24, 2014

Published: February 19, 2015

## REFERENCES

- Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.-W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* 66, 213–221.
- Al-Shami, A., Jhaver, K.G., Vogel, P., Wilkins, C., Humphries, J., Davis, J.J., Xu, N., Potter, D.G., Gerhardt, B., Mullinax, R., et al. (2010). Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development. *PLoS ONE* 5, e13654.
- Boudreaux, D.A., Maiti, T.K., Davies, C.W., and Das, C. (2010). Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation. *Proc. Natl. Acad. Sci. USA* 107, 9117–9122.
- Burgie, S.E., Bingman, C.A., Soni, A.B., and Phillips, G.N., Jr. (2012). Structural characterization of human Uch37. *Proteins* 80, 649–654.
- Carbone, M., Yang, H., Pass, H.I., Krausz, T., Testa, J.R., and Gaudino, G. (2013). BAP1 and cancer. *Nat. Rev. Cancer* 13, 153–159.
- Chen, X., Lee, B.-H., Finley, D., and Walters, K.J. (2010). Structure of proteasome ubiquitin receptor hRpn13 and its activation by the scaffolding protein hRpn2. *Mol. Cell* 38, 404–415.
- Chen, Y., Fu, D., Xi, J., Ji, Z., Liu, T., Ma, Y., Zhao, Y., Dong, L., Wang, Q., and Shen, X. (2012). Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. *Dig. Dis. Sci.* 57, 2310–2317.
- Chia, N.-Y., Chan, Y.-S., Feng, B., Lu, X., Orlov, Y.L., Moreau, D., Kumar, P., Yang, L., Jiang, J., Lau, M.-S., et al. (2010). A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. *Nature* 468, 316–320.
- Clague, M.J., Barsukov, I., Coulson, J.M., Liu, H., Rigden, D.J., and Urbé, S. (2013). Deubiquitylases from genes to organism. *Physiol. Rev.* 93, 1289–1315.
- Cohn, M.A., Kowal, P., Yang, K., Haas, W., Huang, T.T., Gygi, S.P., and D'Andrea, A.D. (2007). A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. *Mol. Cell* 28, 786–797.
- Dang, L.C., Melandri, F.D., and Stein, R.L. (1998). Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. *Biochemistry* 37, 1868–1879.
- Dubin, G. (2005). Proteinaceous cysteine protease inhibitors. *Cell. Mol. Life Sci.* 62, 653–669.
- Ekkebus, R., van Kasteren, S.I., Kulathu, Y., Scholten, A., Berlin, I., Geurink, P.P., de Jong, A., Goerdal, S., Neefjes, J., Heck, A.J.R., et al. (2013). On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. *J. Am. Chem. Soc.* 135, 2867–2870.
- El Oualid, F., Merckx, R., Ekkebus, R., Hameed, D.S., Smit, J.J., de Jong, A., Hilkmann, H., Sixma, T.K., and Ovaa, H. (2010). Chemical synthesis of ubiquitin, ubiquitin-based probes, and diubiquitin. *Angew. Chem. Int. Ed. Engl.* 49, 10149–10153.
- Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* 66, 486–501.
- Evans, P.R., and Murshudov, G.N. (2013). How good are my data and what is the resolution? *Acta Crystallogr. D Biol. Crystallogr.* 69, 1204–1214.
- Faesen, A.C., Dirac, A.M.G., Shanmugham, A., Ovaa, H., Perrakis, A., and Sixma, T.K. (2011). Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. *Mol. Cell* 44, 147–159.
- Fang, Y., Mu, J., Ma, Y., Ma, D., Fu, D., and Shen, X. (2012). The interaction between ubiquitin C-terminal hydrolase 37 and glucose-regulated protein 78 in hepatocellular carcinoma. *Mol. Cell. Biochem.* 359, 59–66.
- Fang, Y., Fu, D., Tang, W., Cai, Y., Ma, D., Wang, H., Xue, R., Liu, T., Huang, X., Dong, L., et al. (2013). Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. *Biochim. Biophys. Acta* 1833, 559–572.
- Geurink, P.P., El Oualid, F., Jonker, A., Hameed, D.S., and Ovaa, H. (2012). A general chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay reagents. *ChemBioChem* 13, 293–297.
- Glaser, F., Pupko, T., Paz, I., Bell, R.E., Bechor-Shental, D., Martz, E., and Ben-Tal, N. (2003). ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. *Bioinformatics* 19, 163–164.
- Goldstein, A.M. (2011). Germline BAP1 mutations and tumor susceptibility. *Nat. Genet.* 43, 925–926.
- Hamazaki, J., Iemura, S., Natsume, T., Yashiroda, H., Tanaka, K., and Murata, S. (2006). A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes. *EMBO J.* 25, 4524–4536.
- Huang, O.W., Ma, X., Yin, J., Flinders, J., Maurer, T., Kayagaki, N., Phung, Q., Bosanac, I., Arnott, D., Dixit, V.M., et al. (2012). Phosphorylation-dependent activity of the deubiquitinase DUBA. *Nat. Struct. Mol. Biol.* 19, 171–175.
- Jiao, L., Ouyang, S., Shaw, N., Song, G., Feng, Y., Niu, F., Qiu, W., Zhu, H., Hung, L.W., Zuo, X., et al. (2014). Mechanism of the Rpn13-induced activation of Uch37. *Protein Cell* 5, 616–630.
- Kabsch, W. (2010). XDS. *Acta Crystallogr. D Biol. Crystallogr.* 66, 125–132.
- Kikuchi, M., Ogishima, S., Miyamoto, T., Miyashita, A., Kuwano, R., Nakaya, J., and Tanaka, H. (2013). Identification of unstable network modules reveals disease modules associated with the progression of Alzheimer's disease. *PLoS ONE* 8, e76162.
- Köhler, A., Schneider, M., Cabal, G.G., Nehrbass, U., and Hurt, E. (2008). Yeast Ataxin-7 links histone deubiquitination with gene gating and mRNA export. *Nat. Cell Biol.* 10, 707–715.
- Köhler, A., Zimmerman, E., Schneider, M., Hurt, E., and Zheng, N. (2010). Structural basis for assembly and activation of the heterotetrameric SAGA histone H2B deubiquitinase module. *Cell* 141, 606–617.
- Komander, D., Clague, M.J., and Urbé, S. (2009). Breaking the chains: structure and function of the deubiquitinases. *Nat. Rev. Mol. Cell Biol.* 10, 550–563.
- Lee, K.K., Florens, L., Swanson, S.K., Washburn, M.P., and Workman, J.L. (2005). The deubiquitylation activity of Ubp8 is dependent upon Sgf11 and its association with the SAGA complex. *Mol. Cell. Biol.* 25, 1173–1182.
- Luna-Vargas, M.P.A., Christodoulou, E., Alfieri, A., van Dijk, W.J., Stadnik, M., Hibbert, R.G., Sahtoe, D.D., Clerici, M., Marco, V.D., Littler, D., et al. (2011). Enabling high-throughput ligation-independent cloning and protein expression for the family of ubiquitin specific proteases. *J. Struct. Biol.* 175, 113–119.
- Maiti, T.K., Permaul, M., Boudreaux, D.A., Mahanic, C., Mauney, S., and Das, C. (2011). Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme. *FEBS J.* 278, 4917–4926.
- Matilainen, O., Arpalaiti, L., Rantanen, V., Hautaniemi, S., and Holmberg, C.I. (2013). Insulin/IGF-1 signaling regulates proteasome activity through the deubiquitinating enzyme UBH-4. *Cell Rep.* 3, 1980–1995.
- McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. *J. Appl. Cryst.* 40, 658–674.
- Misaghi, S., Ottosen, S., Izrael-Tomasevic, A., Arnott, D., Lamkanfi, M., Lee, J., Liu, J., O'Rourke, K., Dixit, V.M., and Wilson, A.C. (2009). Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. *Mol. Cell. Biol.* 29, 2181–2192.
- Morrow, M.E., Kim, M.I., Ronau, J.A., Sheedlo, M.J., White, R.R., Chaney, J., Paul, L.N., Lill, M.A., Artavanis-Tsakonas, K., and Das, C. (2013). Stabilization of an unusual salt bridge in ubiquitin by the extra C-terminal domain of the proteasome-associated deubiquitinase UCH37 as a mechanism of its exo specificity. *Biochemistry* 52, 3564–3578.
- Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997). Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr. D Biol. Crystallogr.* 53, 240–255.
- Nishi, R., Wijnhoven, P., le Sage, C., Tjeertes, J., Galanty, Y., Forment, J.V., Clague, M.J., Urbé, S., and Jackson, S.P. (2014). Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity. *Nat. Cell Biol.* 16, 1016–1026.

- Popp, M.W., Artavanis-Tsakonas, K., and Ploegh, H.L. (2009). Substrate filtering by the active site crossover loop in UCHL3 revealed by sortagging and gain-of-function mutations. *J. Biol. Chem.* **284**, 3593–3602.
- Qiu, X.-B., Ouyang, S.-Y., Li, C.-J., Miao, S., Wang, L., and Goldberg, A.L. (2006). hRpn13/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37. *EMBO J.* **25**, 5742–5753.
- Rzychon, M., Chmiel, D., and Stec-Niemczyk, J. (2004). Modes of inhibition of cysteine proteases. *Acta Biochim. Pol.* **51**, 861–873.
- Samara, N.L., Datta, A.B., Berndsen, C.E., Zhang, X., Yao, T., Cohen, R.E., and Wolberger, C. (2010). Structural insights into the assembly and function of the SAGA deubiquitinating module. *Science* **328**, 1025–1029.
- Sanchez-Pulido, L., Kong, L., and Ponting, C.P. (2012). A common ancestry for BAP1 and Uch37 regulators. *Bioinformatics* **28**, 1953–1956.
- Scheuermann, J.C., de Ayala Alonso, A.G., Oktaba, K., Ly-Hartig, N., McGinty, R.K., Fraterman, S., Wilm, M., Muir, T.W., and Müller, J. (2010). Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. *Nature* **465**, 243–247.
- Smart, O.S., Womack, T.O., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., Vornrhein, C., and Bricogne, G. (2012). Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. *Acta Crystallogr. D Biol. Crystallogr.* **68**, 368–380.
- Smeenk, G., and van Attikum, H. (2013). The chromatin response to DNA breaks: leaving a mark on genome integrity. *Annu. Rev. Biochem.* **82**, 55–80.
- Sommer, S., Weikart, N.D., Linne, U., and Mootz, H.D. (2013). Covalent inhibition of SUMO and ubiquitin-specific cysteine proteases by an in situ thiol-alkyne addition. *Bioorg. Med. Chem.* **21**, 2511–2517.
- Sowa, M.E., Bennett, E.J., Gygi, S.P., and Harper, J.W. (2009). Defining the human deubiquitinating enzyme interaction landscape. *Cell* **138**, 389–403.
- Villamil, M.A., Chen, J., Liang, Q., and Zhuang, Z. (2012). A noncanonical cysteine protease USP1 is activated through active site modulation by USP1-associated factor 1. *Biochemistry* **51**, 2829–2839.
- Wang, L., Du, Y., Ward, J.M., Shimbo, T., Lackford, B., Zheng, X., Miao, Y.-L., Zhou, B., Han, L., Fargo, D.C., et al. (2014). INO80 facilitates pluripotency gene activation in embryonic stem cell self-renewal, reprogramming, and blastocyst development. *Cell Stem Cell* **14**, 575–591.
- White, A.E., and Harper, J.W. (2012). Cancer. Emerging anatomy of the BAP1 tumor suppressor system. *Science* **337**, 1463–1464.
- Wicks, S.J., Haros, K., Maillard, M., Song, L., Cohen, R.E., Dijke, P.T., and Chantry, A. (2005). The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. *Oncogene* **24**, 8080–8084.
- Wicks, S.J., Grocott, T., Haros, K., Maillard, M., ten Dijke, P., and Chantry, A. (2006). Reversible ubiquitination regulates the Smad/TGF-beta signalling pathway. *Biochem. Soc. Trans.* **34**, 761–763.
- Yao, T., Song, L., Xu, W., DeMartino, G.N., Florens, L., Swanson, S.K., Washburn, M.P., Conaway, R.C., Conaway, J.W., and Cohen, R.E. (2006). Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. *Nat. Cell Biol.* **8**, 994–1002.
- Yao, T., Song, L., Jin, J., Cai, Y., Takahashi, H., Swanson, S.K., Washburn, M.P., Florens, L., Conaway, R.C., Cohen, R.E., and Conaway, J.W. (2008). Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in the Ino80 chromatin-remodeling complex. *Mol. Cell* **31**, 909–917.
- Zhou, Z.R., Zhang, Y.H., Liu, S., Song, A.X., and Hu, H.Y. (2012). Length of the active-site crossover loop defines the substrate specificity of ubiquitin C-terminal hydrolases for ubiquitin chains. *Biochem. J.* **441**, 143–149.